CEL-SCI Corp's (CVM) Multikine Phase 3 Trial Receives FDA Clinical Hold
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
CEL-SCI Corporation (NYSE: CVM) announced that it has received verbal notice from the U.S. Food and Drug Administration (FDA) that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold. Pursuant to this communication from FDA, patients currently receiving study treatments can continue to receive treatment, and patients already enrolled in the study will continue to be followed. CEL-SCI was also told to expect a formal letter from the FDA within 30 days and will work diligently with the FDA to obtain the release of the clinical hold. The study currently has about 926 patients enrolled.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Five Prime Therapeutics (FPRX) Announces EC Orphan Drug Designation for Cabiralizumab (FPA008) for PVNS
- Intrexon (XON) to Acquire GenVec (GNVC)
- DexCom (DXCM) Announces Publication of Study in JAMA Demonstrating Value of CGM in Reducing A1C and Hypoglycemia
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News, Hot FDA News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!